There are over a dozen experimental small molecules that are designed to inhibit CGAS and there are several activators and inhibitors of STING1, which are mainly being evaluated in immunological diseases and cancer.71, 72, 73 Concerning CGAS inhibitors, these agents either block the binding of CGAS to DNA, inhibit its catalytic function in generating cGAMP, or affect its activity through post-translational modifications. The gene discussed is STING1; the disease is cancer.